Relationship between sterol carrier protein 2 gene and prostate cancer: Based on single-cell RNA sequencing combined with Mendelian randomization.
- Author:
Jia-Xin NING
1
;
Shu-Hang LUO
1
;
Hao-Ran WANG
1
;
Hui-Min HOU
1
;
Ming LIU
1
Author Information
1. Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China.
- Publication Type:Journal Article
- Keywords:
single-cell RNA sequencing;
mendelian randomization;
prostate cancer;
lipid metabolism;
sterol carrier protein 2 gene
- MeSH:
Humans;
Prostatic Neoplasms/genetics*;
Male;
Mendelian Randomization Analysis;
Polymorphism, Single Nucleotide;
Quantitative Trait Loci;
Single-Cell Analysis;
Sequence Analysis, RNA;
Carrier Proteins/genetics*;
Transcriptome;
Lipid Metabolism
- From:
National Journal of Andrology
2025;31(5):403-411
- CountryChina
- Language:Chinese
-
Abstract:
Objective： To investigate the relationship between the lipid metabolism-related gene sterol carrier protein 2(SCP2) and prostate cancer (PCa) from a multi-omics perspective using single-cell transcriptomes combined with Mendelian randomization. Methods： Single-cell transcriptome data of benign and malignant prostate tissues were obtained from GSE120716, GSE157703 and GSE141445 datasets, respectively. Integration, quality control and annotation were performed on the data to categorize the epithelial cells into high and low SCP2 expression groups, followed by further differential and trajectory analyses. Single nucleotide polymorphism (SNP) data for SCP2 expression quantitative trait loci (eQTL) were subsequently downloaded from Genotype-Tissue Expression (GTEx) and investigated from the PCa Society Cancer-Related Genomic Alteration Panel for the Investigation of Cancer-Related Alterations (PRACTICAL) to obtain PCa outcome data for Mendelian randomization analysis to validate the causal relationship between SCP2 and PCa. Results： High SCP2-expressing epithelial cells had higher energy metabolism and proliferation capacity with low immunotherapy response and metastatic tendency. Trajectory analysis showed that epithelial cells with high SCP2 expression may have a higher degree of malignancy, and SCP2 may be a key marker gene for differentiation of malignant epithelial cells in the prostate. Further Mendelian randomization results showed a significant causal relationship between SCP2 and PCa development (OR=1.045, 95% CI: 1.010 －1.083, P=0.011). Conclusion： By combining single-cell transcriptome and Mendelian randomization, the role of the lipid metabolism-related gene SCP2 in PCa development has been confirmed, and new targets and therapeutic directions for PCa treatment have been provided.
